Skip to main content
Quest Diagnostics

Are Novel Psychoactive Substances on your Radar?

RX and Illicit Drug Summit 2026

Nashville, TN, April 6-9, 2026

Oral presentation: Are Novel Psychoactive Substances on your Radar?

Authors: Meli TM, Neifeld JR, Kain J, Bartock SH

Medical Specialty: Prescription drug monitoring, Toxicology

Related content

Test FAQ
Novel Psychoactive Substances (NPS) Panel
Audio Podcast
Novel Psychoactive Substances (NPS): A Dangerous, Widespread Public Health Issue
On-Demand Webinar
The Growing Crisis of Novel Psychoactive Substances
Conference Presentation
The Prevalence of Other Additive Novel Psychoactive Substances and Polydrug Positivity in Clinical Urine Specimens
Conference Presentation
Oddball NPS: Prevalence and Trends in Clinical Specimens
Test FAQ
Drug Toxicology Monitoring Oral Fluid Testing
Test FAQ
Drug monitoring, Phoshatidylethanol (PEth), Blood Test

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.